Introduction
toxicity, infections, GVHD, Comorbidity
GRAFT-VERSUS-HOST DISEASE, INFECTIONS, SECONDARY, GVHD, COMPLICATIONS
Patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) have a high risk of transplant-related complications such as toxicity, infections, and graft-versus-host disease (GVHD). Approximately 50% of allo-HSCT recipients become long-term survivors [To predict mortality and transplant-related side effects that informs individually adapted clinical care, patients are scored according to standard clinical prognostic scoring systems prior to allo-HSCT, such as the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) and the European Bone Marrow Transplantation (EBMT) risk score. However, these scoring systems do not include patient-reported outcomes (PROs), which not only provide important information for clinical care, but may also predict survival [However, less evidence is available on the potential prognostic value of PRO data in patients undergoing allo-HSCT. Hamilton et al. showed that pre-transplant QoL and physical well-being were associated with reduced risk of overall mortality after allo-HSCT [If, as studies above indicate, PROs are documented to have a prognostic value, it can be relevant to include PROs more systematically in clinical care and follow-up. This could in turn help guide interventions to reduce mortality and morbidity, as well as improving QoL after allo-HSCT.Because of the scarcity of information on the prognostic value of PROs in this group of patients, we conducted a secondary analysis of data from an open randomized controlled trial (RCT) examining a nutrition intervention in patients undergoing allo-HSCT following myeloablative conditioning [